Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus.

Miyake T, Hiasa Y, Hirooka M, Tokumoto Y, Watanabe T, Furukawa S, Ueda T, Yamamoto S, Kumagi T, Miyaoka H, Abe M, Matsuura B, Onji M.

Lipids. 2012 Nov;47(11):1053-62. doi: 10.1007/s11745-012-3716-8. Epub 2012 Sep 16.

PMID:
22983804
[PubMed - indexed for MEDLINE]
2.
3.

Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy.

Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM.

J Viral Hepat. 2013 Nov;20(11):761-9. doi: 10.1111/jvh.12097. Epub 2013 Apr 7.

PMID:
24168255
[PubMed - indexed for MEDLINE]
4.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

PMID:
21443535
[PubMed - indexed for MEDLINE]
5.

Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.

Miyasaka A, Kumagai I, Abe K, Suzuki K.

Hepatogastroenterology. 2012 May;59(115):794-9. doi: 10.5754/hge11570.

PMID:
22020909
[PubMed - indexed for MEDLINE]
6.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

PMID:
23806058
[PubMed - indexed for MEDLINE]
Free Article
7.

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.

Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N.

Hepatology. 2012 Nov;56(5):1611-21. doi: 10.1002/hep.25826.

PMID:
22577043
[PubMed - indexed for MEDLINE]
8.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
[PubMed - indexed for MEDLINE]
9.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
[PubMed - indexed for MEDLINE]
10.

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.

Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS.

PLoS One. 2011 Mar 30;6(3):e18322. doi: 10.1371/journal.pone.0018322.

PMID:
21479134
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

[Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients].

Liu JP, Kang Y, Shang J, Ding GQ, Xiao EH, Wei JF, Cao Q.

Zhonghua Gan Zang Bing Za Zhi. 2013 Sep;21(9):656-8. doi: 10.3760/cma.j.issn.1007-3418.2013.09.003. Chinese.

PMID:
24160338
[PubMed - indexed for MEDLINE]
12.

Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.

Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Med Virol. 2012 Mar;84(3):438-44. doi: 10.1002/jmv.23207.

PMID:
22246829
[PubMed - indexed for MEDLINE]
13.

Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.

Amanzada A, Goralczyk A, Moriconi F, Blaschke M, Schaefer IM, van Thiel D, Mihm S, Ramadori G.

Dig Dis Sci. 2011 Nov;56(11):3296-304. doi: 10.1007/s10620-011-1933-2. Epub 2011 Oct 13.

PMID:
21994136
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.

Grebely J, Hellard M, Applegate T, Petoumenos K, Yeung B, Feld JJ, Rawlinson W, Lloyd AR, George J, Kaldor JM, Dore GJ, Matthews GV; ATAHC Study Group.

AIDS. 2012 Aug 24;26(13):1653-61.

PMID:
22555168
[PubMed - indexed for MEDLINE]
15.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
[PubMed - indexed for MEDLINE]
16.

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.

Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C.

J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9.

PMID:
22863265
[PubMed - indexed for MEDLINE]
17.

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597.

PMID:
23918536
[PubMed - indexed for MEDLINE]
18.

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23.

PMID:
21745312
[PubMed - indexed for MEDLINE]
19.

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.

Petta S, Ferraro D, Cammà C, Cabibi D, Di Cristina A, Di Marco V, Di Stefano R, Grimaudo S, Mazzola A, Levrero M, Scazzone C, Craxì A.

Antivir Ther. 2012;17(5):823-31. doi: 10.3851/IMP2100. Epub 2012 Apr 13.

PMID:
22505587
[PubMed - indexed for MEDLINE]
20.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

PMID:
22924160
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk